Drug Trial Radar · NCT07824323
Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome
Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Aug 26, 2026
Primary completion
Mar 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Taipei Medical University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized clinical trial will evaluate whether starting bempedoic acid in addition to high-intensity statin therapy and ezetimibe within 72 hours after percutaneous coronary intervention improves low-density lipoprotein cholesterol (LDL-C) control in adults with acute coronary syndrome. Participants will receive either triple therapy with a high-intensity statin, ezetimibe, and bempedoic acid or standard dual therapy with a high-intensity statin and ezetimibe for 12 weeks. The primary outcome is the proportion of participants with LDL-C below 55 mg/dL at Week 12. Changes in lipid and inflammatory markers, medication adherence, and treatment-emergent adverse events will also be assessed.
Conditions
- Acute Coronary Syndromes
- Dyslipidemia
Interventions
bempedoic acidDrug
Bempedoic acid 180 mg tablet taken orally once daily for 12 weeks.
EzetimibeDrug
Ezetimibe 10 mg tablet taken orally once daily for 12 weeks.
High-Intensity Statin TherapyDrug
Atorvastatin 40 mg orally once daily or rosuvastatin 20 mg orally once daily for 12 weeks, selected according to clinical judgment and routine practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants Achieving LDL-C Below 55 mg/dL at Week 12Time frame: Week 12 (visit window: +/- 2 weeks)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Taipei Medical University Hospital
Taipei, Taipei City, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.